Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (3) , 176-181
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Cancer Institute
This publication has 29 references indexed in Scilit:
- Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation ModelJCO Clinical Cancer Informatics, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA TrialJournal of Clinical Oncology, 2016
- Treatment of patients with transformed lymphomaHematology-American Society Hematology Education Program, 2015
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaNew England Journal of Medicine, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphomaBlood, 2014
- Genetics of Follicular Lymphoma TransformationCell Reports, 2014
- Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008